Telling the big stories about new technologies and how they will change our lives is what Technology Review has always done best. We don't get particularly excited about whether Google's stock price is $380 or $420, or how GlaxoSmithKline plans to market its latest pill. But we do care about Google's grand strategy to become the mediator of almost every type of online information exchange and are interested in how Glaxo and its competitors plan to invent the next generation of life-extending pharmaceuticals. Covering these big stories is what our bimonthly-magazine format -- with its deep well of feature pages, longer lead times, and high-quality graphics and photography -- is designed to support.

Select from the choices above to read the entire article.